CAMP4 THERAPEUTICS CORP (CAMP) Stock News

USA - Nasdaq - NASDAQ:CAMP - US13463J1016 - Common Stock

3.595 USD

-0.05 (-1.51%)

Last: 12/9/2025, 11:15:03 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CAMP Latest News, Press Relases and Analysis

All

Press Releases

10 days ago - By: The Motley Fool - Mentions: CNTA SKYE TRDA PHVS

What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company

21 days ago - By: The Motley Fool - Mentions: VKTX SKYE TRDA PHVS ...

5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity?

25 days ago - By: CAMP4 Therapeutics

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

8 months ago - By: Benzinga - Mentions: GNFT EWTX

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2

25 days ago - By: CAMP4 Therapeutics

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: CAMP4 Therapeutics

CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights

a month ago - By: CAMP4 Therapeutics

CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights

2 months ago - By: CAMP4 Therapeutics

CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01

2 months ago - By: CAMP4 Therapeutics

CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01

3 months ago - By: Benzinga - Mentions: KEQU BLRX VNRX RNA ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

3 months ago - By: CAMP4 Therapeutics

CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders

3 months ago - By: CAMP4 Therapeutics

CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders

4 months ago - By: CAMP4 Therapeutics

CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights

4 months ago - By: CAMP4 Therapeutics

CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights

7 months ago - By: CAMP4 Therapeutics

CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American

7 months ago - By: CAMP4 Therapeutics

CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American

7 months ago - By: CAMP4 Therapeutics

CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights

7 months ago - By: CAMP4 Therapeutics

CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights

7 months ago - By: CAMP4 Therapeutics

CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting

7 months ago - By: CAMP4 Therapeutics

CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting

9 months ago - By: CAMP4 Therapeutics

CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

9 months ago - By: CAMP4 Therapeutics

CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

9 months ago - By: CAMP4 Therapeutics

CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

9 months ago - By: CAMP4 Therapeutics

CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

10 months ago - By: CAMP4 Therapeutics

CAMP4 to Participate in Upcoming Investor Conferences

10 months ago - By: CAMP4 Therapeutics

CAMP4 to Participate in Upcoming Investor Conferences